论文部分内容阅读
目的探讨磺脲类(SUs)降糖药对糖尿病合并急性心肌梗死(AMI)患者住院病死率的影响。方法回顾性收集AMI患者(糖尿病365例,无糖尿病1803例)住院期间临床资料,分析糖尿病患者AMI发生时使用SUs药物是否对其预后具有独立影响。结果糖尿病患者AMI的住院病死率明显高于同期非糖尿病AMI患者(22.2%vs 13.2%,P<0.01)。在糖尿病合并AMI患者中,使用SUs药物的患者住院期间病死率低于非SUs药物治疗者(13.8%vs 32.4%)。多因素回归分析显示,AMI发生时使用SUs药物是糖尿病合并AMI患者的保护因素。结论 AMI住院期间使用SUs药物不会增加糖尿病患者AMI的住院病死率。
Objective To investigate the effect of sulfonylureas (SUs) hypoglycemic agents on in-hospital mortality in patients with diabetes mellitus (AMI) complicated with acute myocardial infarction (AMI). Methods The clinical data of AMI patients (365 cases of diabetes mellitus and 1803 cases of no diabetes mellitus) during hospitalization were retrospectively analyzed. Whether the use of SUs in AMI patients with diabetes mellitus was independent of prognosis was analyzed. Results The in-hospital mortality rate of AMI in diabetic patients was significantly higher than that of non-diabetic AMI patients in the same period (22.2% vs 13.2%, P <0.01). Among patients with diabetes mellitus and those with AMI, those using SUs drugs had lower in-hospital mortality than non-SUs drug-treated patients (13.8% vs 32.4%). Multivariate regression analysis showed that the use of SUs in AMI was a protective factor in diabetic patients with AMI. Conclusions The use of SUs during AMI hospitalization does not increase the in-hospital mortality rate of AMI in diabetic patients.